209467-52-7
209467-52-7 结构式
基本信息
BAL 9141
Ceftobiprole
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(5-aMino-1,2,4-thiadiazol-3-yl)-2-(hydroxyiMino)acetyl]aMino]-8-oxo-3-[(E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]Methyl]-,(6R,7R)-
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-112579 | 头孢吡普 Ceftobiprole | 209467-52-7 | 5mg | 3100元 |
| 2024/04/30 | HY-112579 | 头孢吡普 Ceftobiprole | 209467-52-7 | 10mg | 4500元 |
| 2024/04/30 | HY-112579 | 头孢吡普 Ceftobiprole | 209467-52-7 | 25mg | 7200元 |
常见问题列表
MIC90: 2 μg/mL (MRSA)
Ceftobiprole has demonstrates activity against important gram-positive bacteria, including S. pneumonia (PRSP), Methicillin-resistant S. aureus (MRSA), and E. faecalis with MIC 90 values of 0.25, 2, and 2 mcg/mL, respectively. Ceftobiprole has also demonstrated potent in vitro activity against several clinical isolates of community-associated Methicillin-resistant S. aureus (CA-MRSA), S. aureus (VISA), and S. aureus (VRSA), with a minimum inhibitory concentration (MIC) of 2 mcg/mL. Ceftobiprole is highly active against S. aureus, withMICs ranging from 0.12 to 4 mg/L (only one resistant strain,MIC of 4 mg/L). Furthermore, Ceftobiprole is twice more active on Methicillin-susceptible S. aureus (MSSA) strains with MIC 50 and MIC 90 of 0.5 mg/L than on MRSA strains with MIC 50 and MIC 90 of 1 mg/L. Moreover, Panton-Valentine leukocidin (PVL)+MRSA are slightly more susceptible to Ceftobiprole (MIC 50 of 0.5 mg/L and MIC 90 of 1 mg/L) than PVL-MRSA (MIC 50 and MIC 90 of 1 mg/L).